For research use only. We do not sell to patients.
Ionizable lipids / GalNAc Lipid GL6(GalNAc Lipid 1004)
GalNAc Lipid GL6(GalNAc Lipid 1004) chemical structure
Product imageResearch use only
CAT. NO. DC60502Featured

GalNAc Lipid GL6(GalNAc Lipid 1004)

Pack size & price

USD
TotalPrice on request
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

GL6 is a trivalent GalNAc lipid ligand studied as an ASGPR-targeting component of lipid nanoparticles. In mouse and cynomolgus-monkey experiments it enabled hepatic ANGPTL3 base editing despite LDLR deficiency. GL6 is the targeting component of a multi-lipid formulation; the ionizable amino lipid used in the paper was not structurally disclosed.

Open full Formulation & Performance →

Literature evidence · DC60502

Formulation & Performance

Hepatic targeting evidence from the 2023 Nature Communications paper and its complete supporting information.

The paper identifies GL6 as a lysine-scaffold GalNAc ligand with a PEG spacer and a DSG lipid anchor. GalNAc Lipid 1004 is retained as the catalog alias. Commercial molecular-weight and formula values are catalog specifications; the paper describes an average PEG spacer length.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
Undisclosed ionizable amino lipidNot uniquely mappedNot established55Not calculable from disclosed data
CholesterolDCD-041386.6538.150.147507
DSPCDC57005790.154.70.037137
PEG-lipid, exact identity undisclosedNot uniquely mappedNot established2.1Not calculable from disclosed data
GalNAc Lipid GL6DC605023449.380.050.001725

Methods give the four-base-lipid molar percentages for some mouse studies; the listed 0.05% GL6 condition completes a nominal 100%. These values are not assumed to define every mouse batch or the NHP formulation. The NHP table confirms 0.05% GL6 but does not disclose the full composition. Exact amino-lipid and PEG-lipid MWs are unavailable.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
Undisclosed ionizable amino lipid——
Cholesterol——
DSPC——
PEG-lipid, exact identity undisclosed——
GalNAc Lipid GL6——

Mouse formulation characterization

Table S1 entry / figureCargo targetGL6 mol%Size nmPDIRNA entrapment %
1 / 1dAngptl30.0598.610.01394.91
3 / 1ePcsk9; post-insertion0.579.30.07294.7
6 / 1f,gAngptl30.05100.40.03493.59
11 / 2bAngptl30.0598.610.01394.91
16 / 2cAngptl30.0566.730.01898.36
17 / 2dAngptl30.0577.240.02899.2

SI Table S1, p. 1. These are separate preparations; entry 3 uses post-insertion. Do not merge their particle values.

Primate formulation characterization

Table S2 entryGL6 mol%Size nmPDIRNA entrapment %RNA dose
1074.970.05792.62 mg/kg
2072.730.03294.32 mg/kg
30.0572.930.08393.62 mg/kg
40.0571.970.04293.32 mg/kg

SI Table S2, p. 2; two standard and two GL6-containing preparations. No N/P or undisclosed amino-lipid identity is inferred.

Mouse efficacy: matched comparisons

ComparisonOutcomeModel / source
GL6 vs GL3Mean Angptl3 editing 31% vs 23%; p=0.0086.Ldlr-null mice, 0.1 mg/kg; n=5/group; Fig. 1d.
GL6 vs GL3Mean Pcsk9 editing 43% vs 33%; p=0.01.Ldlr-null mice, 0.25 mg/kg; n=5/group; Fig. 1e.
GL6 vs shorter-spacer GL5Mean Angptl3 editing 56% vs 18%; p<0.0001.Ldlr-null mice, 0.3 mg/kg; n=4-5/group; Fig. 1f.
Addition of 0.05% GL6Editing increased from 9% to 39% in Ldlr-null mice; p<0.0001.0.25 mg/kg; Fig. 2c. Comparable delivery was retained in WT and heterozygous animals.

Liver editing was assessed 5-10 days after dosing. Values are reported study means, not a customer performance specification.

Nonhuman-primate efficacy and durability

EndpointResultContext
Liver ANGPTL3 editingMean 61% with GalNAc-LNPs vs 5% with standard LNPs.Somatic LDLR-deficient cynomolgus monkeys, 2 mg/kg RNA; six GL6-treated animals across studies; Fig. 3e.
ANGPTL3 protein89% reduction in the LDLR-deficient model.Fig. 3f; distinct from percentage liver DNA editing.
LDL cholesterolApproximately 35% reduction, about 100 mg/dL, maintained for three months.LDLR-deficient model; Fig. 3g.
Longer follow-upSustained ANGPTL3 protein reduction assessed through six months.Wild-type monkeys; Fig. 3h. This does not establish six-month persistence of lipid or RNA.
Extrahepatic editingLow editing in the assessed non-liver tissues.Fig. 4; tissue sampling and limits of the study apply.

Tolerability and study limits

GroupReported observationsBoundary
LDLR-deficient NHPsMaximal mean ALT 480 U/L at 48 h; AST 537 U/L at 6 h; both returned to baseline by day 14.Main text and SI Fig. S5; AST was not significantly different from vehicle in the cited comparison.
Wild-type NHPsMaximal mean ALT 710 U/L at 48 h; AST 650 U/L at 6 h; both normalized by day 14.Transient TNF-alpha and MCP-1 increases peaked at 24 h and returned toward baseline within 7 days.
InterpretationAuthors describe tolerability with transient biochemical/cytokine changes.Animals received premedication. The findings are not evidence of no toxicity or clinical safety.

Original study figures

Figure 2: Mouse hepatic editing
Figure 2: Mouse hepatic editing
Kasiewicz et al. (2023), Figure 2. Original, unmodified figure: ligand structure and mouse comparisons; complete caption at source. Original source and caption · CC BY 4.0
Figure 3: Primate editing and durability
Figure 3: Primate editing and durability
Kasiewicz et al. (2023), Figure 3. Original, unmodified figure; model-generation panels and therapeutic studies are distinct. Complete caption at source. Original source and caption · CC BY 4.0
Figure 4: Tissue editing distribution
Figure 4: Tissue editing distribution
Kasiewicz et al. (2023), Figure 4. Original, unmodified figure; complete caption at source. Original source and caption · CC BY 4.0

References and source locations

  1. Kasiewicz LN et al. GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nature Communications 14, 2776 (2023). DOI: 10.1038/s41467-023-37465-1.
  2. Supporting Information: Tables S1-S2 and Figures S1-S5.
CAS No.Not available
Chemical NameGalNAc Lipid GL6(GalNAc Lipid 1004)
SynonymsGalNAc Lipid-GL6
SMILESCCCCCCCCCCCCCCCCCCOC[C@H](COC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NC(CCCCNC(=O)CCCCOC1OC(CO)C(O)C(O)C1NC(C)=O)C(=O)N(CCCNC(=O)CCCCOC1OC(CO)C(O)C(O)C1NC(C)=O)CCCNC(=O)CCCCOC1OC(CO)C(O)C(O)C1NC(C)=O)OCCCCCCCCCCCCCCCCCC
FormulaC166H319O63N9
M.Wt3,449.38
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Kasiewicz LN et al. GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nature Communications 14, 2776 (2023). DOI: 10.1038/s41467-023-37465-1.
  2. Supporting Information: Tables S1-S2 and Figures S1-S5.
F&PFormulation & PerformanceComposition, study results and referencesRead online →
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg2.8991 mL579.81 μL289.91 μL
25 mg7.2477 mL1.4495 mL724.77 μL
50 mg14.4954 mL2.8991 mL1.4495 mL
100 mg28.9907 mL5.7981 mL2.8991 mL
250 mg72.4768 mL14.4954 mL7.2477 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.